Veronique Nussenblatt
Overview
Explore the profile of Veronique Nussenblatt including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
24
Citations
441
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Singh K, Rocco J, Nussenblatt V
Semin Hematol
. 2024 Oct;
61(5):321-332.
PMID: 39379249
Adoptive cellular therapies (ACT) are novel, promising treatments for life-threatening malignancies. In addition to the better known chimeric antigen receptor (CAR) T cells, ACTs include tumor infiltrating lymphocytes (TIL), cancer...
2.
Pechacek J, Schmitt M, Ferre E, Webb T, Goldberg J, Pathan S, et al.
Open Forum Infect Dis
. 2024 Aug;
11(8):ofae428.
PMID: 39091644
is a rare cause of cutaneous and systemic infection that requires long treatment courses with potentially toxic medications. We describe a patient with cutaneous protothecosis refractory to triazole monotherapy who...
3.
Van Dijck C, Crozier I, Vercauteren K, Brosius I, Mbala-Kingebeni P, Dodd L, et al.
Clin Microbiol Infect
. 2023 Sep;
30(3):276-278.
PMID: 37741622
No abstract available.
4.
McNeil A, House D, Mbala-Kingebeni P, Mbaya O, Dodd L, Cowen E, et al.
J Invest Dermatol
. 2022 Sep;
143(2):347-350.e4.
PMID: 36116509
No abstract available.
5.
Suh G, Lodise T, Tamma P, Knisely J, Alexander J, Aslam S, et al.
Antimicrob Agents Chemother
. 2022 Jan;
66(3):e0207121.
PMID: 35041506
Increasing antimicrobial resistance and medical device-related infections have led to a renewed interest in phage therapy as an alternative or adjunct to conventional antimicrobials. Expanded access and compassionate use cases...
6.
Nussenblatt V, Roder A, Das S, de Wit E, Youn J, Banakis S, et al.
J Infect Dis
. 2021 Dec;
225(7):1118-1123.
PMID: 34940844
B-cell-depleting therapies may lead to prolonged disease and viral shedding in individuals infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and this viral persistence raises concern for viral evolution....
7.
Campione A, Lanzieri T, Ricotta E, Grosse S, Kadri S, Nussenblatt V, et al.
Curr Med Res Opin
. 2021 Nov;
38(2):273-275.
PMID: 34775876
Congenital cytomegalovirus (CMV) is a leading cause of non-genetic sensorineural hearing loss and neurodevelopmental disabilities among US children. Studies using administrative healthcare databases have identified infants with congenital CMV using...
8.
Nussenblatt V, Roder A, Das S, de Wit E, Youn J, Banakis S, et al.
medRxiv
. 2021 Oct;
PMID: 34642697
Background: B-cell depleting therapies may lead to protracted disease and prolonged viral shedding in individuals infected with SARS-CoV-2. Viral persistence in the setting of immunosuppression raises concern for viral evolution....
9.
Mikkilineni L, Yates B, Steinberg S, Shahani S, Molina J, Palmore T, et al.
Blood Adv
. 2021 Oct;
5(23):5312-5322.
PMID: 34619768
Infections are a known complication of chimeric antigen receptor (CAR) T-cell therapy with data largely emerging from CD19 CAR T-cell targeting. As CAR T-cell therapy continues to evolve, infection risks...
10.
Masih K, Ligon J, Yates B, Shalabi H, Little L, Islam Z, et al.
Pediatr Blood Cancer
. 2021 Jul;
68(10):e29247.
PMID: 34309174
Serious bacterial infections (SBI) can lead to devastating complications with CD19 CAR T cells and cytokine release syndrome (CRS). Little is known about consequences of and risk factors for SBI...